Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma <i>in vitro</i> and <i>in vivo</i>
Georg Karpel‐Massler(Columbia University Irving Medical Center), Markus D. Siegelin(Columbia University Irving Medical Center)
Cited by 52
Related Papers
HDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
|Journal of Clinical Investigation|2020|204
TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners <i>in vitro</i> and <i>in vivo</i>
|Oncotarget|2015|65